Clinical Trial Update: A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers [Phase 2]

View source ↗

Summary

Phase 2 study evaluating YH003 in combination with toripalimab in patients with melanoma and pancreatic ductal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Toripalimab (Toripalimab)
• YH003 (YH003)

Snippet

Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Conditions: Melanoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED